|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000008004 |
|
Date of registration:
|
21/05/2012 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD in allo-HSCT patients
|
|
Scientific title:
|
Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD in allo-HSCT patients - Efficacy and safety of tacrolimus extended-ralease formulation |
|
Date of first enrolment:
|
2012/05/01 |
|
Target sample size:
|
15 |
|
Recruitment status: |
Pending |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009408 |
|
Study type:
|
Observational |
|
Study design:
|
Not selected Not selected
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
|
|
Address:
|
Japan |
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Tokyo Women's Medical University Department of Hematology |
|
|
Name:
|
Toshiko Motoji |
|
Address:
|
8-1 Kawada-cho, Shinjuku-ku, Tokyo
Japan |
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Tokyo Women's Medical University Department of Hematology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1. patients who had allergic reaction to tacrolimus 2. patients with the administration ofcyclosporin A or bosentan 3. patients with the administration of potassium-conserving diuretic 4. patients who are pregnant or have the possiblity of pregnancy
Age minimum:
20years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
allo hematopoietic stem cell transplantations of hematopoietic disorders
|
|
Primary Outcome(s)
|
|
Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD
|
|
Source(s) of Monetary Support
|
|
Tokyo Women's Medical University
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|